CAS: 957-56-2; 2-(4-Fluorophenyl)-1H-Indene-1,3(2H)-Dione

该化合物是一种属于维生素K敌国的抗凝胶药物,主要用于预防和治疗血栓栓塞症,如深血管血栓和肺栓塞.氟丁二酮的化学结构为1,3-indione核心,这是其药理活动必不可少的.作为合成化合物,它表现出高度的脂性,允许人体内有效吸收和分配.氟丁二酮功能,抑制肝脏中依赖维生素K的凝固因素合成,从而减少血液凝固能力.其血压包括相对长的半衰期,这就要求仔细监测凝固参数,以避免诸如出血等并发症.此外,氟丁二酮可能与各种药物和饮食因素相互作用,使病人在治疗过程中得到重要的管理.总的来说,氟丁二酮是抗凝固疗法中的一个重要剂,尽管其使用在支持新替代品方面减少了,而且与新替代品的相互作用也减少了,但这种相互作用也减少了.

结构式图片

物理性质

MSDS等安全信息

上下游产品

CAS号131-11-3 邻苯二甲酸二甲酯； 避蚊酯 | CAS号620-97-3 1-(4-fluorophen... | CAS号2558-18-1 3-[(4-氟苯基)亚甲基]苯酞 | CAS号85-44-9 苯酐 | CAS号405-50-5 对氟苯乙酸

合成工艺路线路线简述

    📜3-[(4-氟苯基)亚甲基]苯酞置于sodium Methylate体系中,化学反应生成 氟茚二酮
    参考文献:Eckstein Et Al.,Bulletin De L'Academie Polonaise Des Sciences,Serie Des Sciences Chimiques,1959,Vol. 7,P. 289,290
    标题:Eckstein Et Al.,Bulletin De L'Academie Polonaise Des Sciences,Serie Des Sciences Chimiques,1959,Vol. 7,P. 289,290

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-10814013-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-A2
    优先权日:2006-10-05
    标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-A1
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:US-2008107598-A1
    优先权日:2006-10-05
    标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications

    专利号:AU-2007308022-B2
    优先权日:2006-10-05
    标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Moreau C, Pautas E, Duverlie C, Berndt C, Andro M, Mahé I, Emmerich J, Lacut K, Le Gal G, Peyron I, Gouin-Thibault I, Golmard JL, Loriot MA, Siguret V. A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone. Thromb Haemost. 2014 Apr 1;111(4):705-12. doi: 10.1160/TH13-07-0555. Epub 2013 Dec 12. doi: 10.1016/j.revmed.2013.11.017. Epub 2013 Dec 27. French. doi: 10.1016/j.lpm.2013.06.018. Epub 2013 Nov 1. French. Evaluation of a mobile electronic assistant to aid in fluindione prescription: the INRPlus cluster randomized trial. Thromb Res. 2014 May;133(5):756-61. doi: 10.1016/j.thromres.2014.02.003. Epub 2014 Feb 11. doi: 10.1111/hae.12502. Epub 2014 Nov 24. doi: 10.1155/2016/9818195. Epub 2016 Apr 5.
    7: Cam G, Kwetcheu AT, Vigneau C, Siohan P, Queffeulou G, Gatault P, Laruelle E, Crémault A, Le Cacheux P, Rioux-Leclercq N, Renaudineau E. Acute and chronic nephropathy induced by fluindione must be addressed. Nephrol Dial Transplant. 2012 Apr;27(4):1554-8. doi: 10.1093/ndt/gfr500. Epub 2011 Sep 19. doi: 10.1038/clpt.2011.309.
    9: Daveluy A, Milpied B, Barbaud A, Lebrun-Vignes B, Gouraud A, Laroche ML, Ciobanu E, Bégaud B, Moore N, Miremont-Salamé G, Haramburu F; French Pharmacovigilance Centres Network and The Toxidermia Group of the French Society of Dermatology. Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect? Eur J Clin Pharmacol. 2012 Jan;68(1):101-5. doi: 10.1007/s00228-011-1101-9. Epub 2011 Jul 27. doi: 10.1111/j.1365-2125.2011.04095.x.

    合成参考文献


    摘要:Medicina et Pharmacologia Experimentalis., 17(497), 1967 []
    参考文献:10.1016/j.thromres.2006.04.006
    摘要:Bardin N, Pommier G, Sanmarco M. Can cryoglobulins interfere with the measurement of IgM antiphosphatidylethanolamine antibodies by ELISA Thromb Res. 2007;119(4):441–6. doi: 10.1016/j.thromres.2006.04.006.
    参考文献:10.1016/j.jmv.2009.11.004
    摘要:Berrady R, Khammar Z, Lamchachti L, Lahlou M, Rabhi S, Bono W. [Thrombosis of the inferior vena cava revealing primary antiphospholipid syndrome: a case report]. J Mal Vasc. 2010 Feb;35(1):47–50. doi: 10.1016/j.jmv.2009.11.004.
    参考文献:10.1016/j.amjmed.2011.01.016
    摘要:Pautas E, Peyron I, Bouhadiba S, Golmard J, Gouronnec A, Oboa N, Siguret V, Gouin-Thibault I. Reversal of Overanticoagulation in Very Elderly Hospitalized Patients with an INR above 5.0: 24-Hour INR Response after Vitamin K Administration. The American Journal of Medicine. 2011 Jun;124(6):527–33. doi: 10.1016/j.amjmed.2011.01.016.
    参考文献:10.2515/therapie/2012057
    摘要:Bauler S, Janoly-Dumenil A, Sancho PO, Fromager F, Gouraud A, Rioufol C, Jacquin-Courtois S, Luaute J, Rode G. Effect of carbamazepine on fluindione's anticoagulant activity: a case report. Therapie. 2012 Sep;67(5):488–9. doi: 10.2515/therapie/2012057.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知